Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Rachel Schiff, Chandandeep Nagi et al.|Clinical Cancer Research|2019Cited by 87
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Rachel Schiff, H. Shelton Brown et al.|British Journal of Cancer|2018Cited by 65
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancerRaksha R. Bhat, Meghana V. Trivedi, Hariprasad Thangavel et al.|Scientific Reports|2022Cited by 27
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Rachel Schiff, Resel Pereira et al.|Cell Reports|2023Cited by 20
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancerMaria Letizia Cataldo, Bianca Maria Veneziani, Pietro De Placido et al.|Frontiers in Oncology|2023Cited by 18